<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1647">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139719</url>
  </required_header>
  <id_info>
    <org_study_id>HEC585-PF-202</org_study_id>
    <nct_id>NCT05139719</nct_id>
  </id_info>
  <brief_title>Phase ll Study of HEC585 in Patients With PF-ILD</brief_title>
  <official_title>A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Parallel-group ,Adaptive Design Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With Progressive-fibrosing Interstitial Lung Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in&#xD;
      patients with progressive-fibrosing interstitial lung diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Week 24 in %FVC compared with placebo</measure>
    <time_frame>up to 24 Weeks</time_frame>
    <description>change in %FVC, measured using Spirometer, from baseline to week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in %FVC compared with placebo</measure>
    <time_frame>up to 12 Weeks</time_frame>
    <description>change in %FVC, measured using Spirometer, from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an decline from baseline in FVC (% predicted) of &gt; 10%</measure>
    <time_frame>up to 24 Weeks</time_frame>
    <description>The proportion of subjects whose %FVC decline from baseline by more than 10% in each treatment group at W24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first acute ILD exacerbation</measure>
    <time_frame>up to 24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Progressive Fibrosing Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>HEC585 tables does A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC585 dose A once daily, up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HEC585 tables does B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC585 dose B once daily, up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily, up to 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC585</intervention_name>
    <description>HEC585 Tablets，once daily</description>
    <arm_group_label>HEC585 tables does A</arm_group_label>
    <arm_group_label>HEC585 tables does B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo，once daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteer to participate in this clinical study and sign the ICF before the study&#xD;
             begins;&#xD;
&#xD;
          2. Male or female patients aged &gt; or = 18 years .&#xD;
&#xD;
          3. Patients with physician diagnosed Interstitial Lung Disease (ILD) who fulfil at least&#xD;
             one of the following criteria for Progressive Fibrosing Interstitial Lung Disease&#xD;
             (PF-ILD) within 24 months of screening visit despite treatment with unapproved&#xD;
             medications(Unapproved medications used in the clinical practice to treat ILD include&#xD;
             but are not limited to corticosteroid, azathioprine, mycophenolate mofetil (MMF),&#xD;
             n-acetylcysteine (NAC), rituximab, cyclophosphamide, cyclosporine, tacrolimus) used in&#xD;
             clinical practice to treat ILD, as assessed by the investigator:&#xD;
&#xD;
               1. Clinically significant decline in Forced Vital Capacity (FVC) % pred based on a&#xD;
                  relative decline of &gt;=10%;&#xD;
&#xD;
               2. Marginal decline in FVC % pred based on a relative decline of .&gt; or =5 combined&#xD;
                  with decline in Carbon Monoxide Diffusion Capacity (DLCO) corrected for&#xD;
                  Haemoglobin (Hb) &gt; or = 15% .&#xD;
&#xD;
               3. Marginal decline in FVC % pred based on a relative decline of .&gt; or =5 combined&#xD;
                  with worsening of respiratory symptoms&#xD;
&#xD;
               4. Marginal decline in FVC % pred based on a relative decline of &gt; or =5 combined&#xD;
                  with increasing extent of fibrotic changes on chest imaging&#xD;
&#xD;
               5. Worsening of respiratory symptoms as well as increasing extent of fibrotic&#xD;
                  changes on chest imaging Note: Changes attributable to comorbidities e.g.&#xD;
                  infection, heart failure must be excluded.&#xD;
&#xD;
          4. Fibrosing lung disease on HRCT, defined as reticular abnormality with traction&#xD;
             bronchiectasis with or without honeycombing, with disease extent of &gt;10% as confirmed&#xD;
             by central readers.&#xD;
&#xD;
          5. For patients with underlying Connective Tissue Disease (CTD): stable CTD as defined by&#xD;
             no initiation of new therapy or withdrawal of therapy for CTD within 6 weeks prior to&#xD;
             screening period.&#xD;
&#xD;
          6. FEV1/FVC&gt;or=0.7 before using bronchodilators.&#xD;
&#xD;
          7. FVC &gt; or = 45% predicted .&#xD;
&#xD;
          8. Carbon Monoxide Diffusion Capacity (DLCO) corrected for Haemoglobin (Hb) &gt; or = 30%&#xD;
             and &lt;80% predicted of normal.&#xD;
&#xD;
          9. Female or male subjects agreed and promised to use effective contraception .&#xD;
&#xD;
         10. Subjects are willing and able to comply with the protocol requirements and attend the&#xD;
             visit assessed by investigators.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Idiopathic Pulmonary Fibrosis (IPF).&#xD;
&#xD;
          2. Lung with other clinically significant abnormalities which investigator assess to have&#xD;
             an effect on the results of study.&#xD;
&#xD;
          3. Significant Pulmonary Arterial Hypertension (PAH) defined by any of the following:&#xD;
&#xD;
             Previous clinical or echocardiographic evidence of significant right heart failure&#xD;
             History of right heart catheterization showing a cardiac index &lt;= 2 l/min/m² PAH&#xD;
             requiring parenteral therapy with epoprostenol/treprostinil.&#xD;
&#xD;
          4. Major extrapulmonary physiological restriction (e.g. chest wall abnormality, large&#xD;
             pleural effusion)&#xD;
&#xD;
          5. Expected to receive lung transplantation during the study.&#xD;
&#xD;
          6. Expected survival is less than 6 months.&#xD;
&#xD;
          7. History of tumors within 5 years before screening (except for localized cancers such&#xD;
             as basal cell carcinoma)&#xD;
&#xD;
          8. Thyroid dysfunction that the investigator assessed to be clinically significant and&#xD;
             needed to be treated.&#xD;
&#xD;
          9. History of unstable or worsening heart disease during the 6 months prior to screening,&#xD;
             including but not limited to the following:&#xD;
&#xD;
               1. Myocardial infarction ;&#xD;
&#xD;
               2. Unstable cardiac angina ;&#xD;
&#xD;
               3. Congestive heart failure (need to be treated in hospital or NYHA III/IV);&#xD;
&#xD;
               4. Uncontrolled severe arrhythmias.&#xD;
&#xD;
         10. TBIL &gt;1.2 × ULN ； AST or ALT &gt; 1.5 × ULN.&#xD;
&#xD;
         11. CLcr&lt;60ml/min&#xD;
&#xD;
         12. Human immunodeficiency virus (HIV) antibody is positive.&#xD;
&#xD;
         13. Uncontrolled hepatitis B virus infection or hepatitis C virus infection.&#xD;
&#xD;
         14. Use of any of the following medications for the treatment of Interstitial Lung Disease&#xD;
             (ILD):&#xD;
&#xD;
               1. Strong inducers or strong CYP3A4 inhibitors within 4 weeks before randomization;&#xD;
&#xD;
               2. Azathioprine (AZA), cyclosporine, MMF, tacrolimus, oral corticosteroids (OCS)&#xD;
                  &gt;20mg/day and the combination of OCS+AZA+NAC within 4 weeks before randomization;&#xD;
&#xD;
               3. Cyclophosphamide within 8 weeks before randomization;&#xD;
&#xD;
               4. Pirfenidone or nintedanib within 3 months before randomization,or have a history&#xD;
                  of continuous treatment with pirfenidone or nidanib for ≥3 months;&#xD;
&#xD;
               5. Rituximab within the 6 months before randomization.&#xD;
&#xD;
         15. Subjects canot complete the PFT、6MWT,or questionaires.&#xD;
&#xD;
         16. Allergic to any component of HEC585 Tablets or pirfenidone tablets.&#xD;
&#xD;
         17. Participated in other clinical study and received the last dose within 3 months before&#xD;
             screening.&#xD;
&#xD;
         18. Pregnant or breastfeeding.&#xD;
&#xD;
         19. History of smoking within 3 months before screening or are unwilling to quit smoking&#xD;
             during the study.&#xD;
&#xD;
         20. History of alcohol or drug abuse within 6 months before the screening;&#xD;
&#xD;
         21. Any condition that, in the opinion of the investigator, would compromise the safety or&#xD;
             compliance of the subject, or prevent the subject from completing the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>HuaPing Dai, Master</last_name>
    <phone>010-84206278</phone>
    <email>daihuaping@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

